Pharma R&D Annual Review 2022

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.

whitePaper | April 20, 2023

Welcome to Pharmaprojects’ 2023 review of trends in pharmaceutical R&D. For over 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article, I’llexamine the state of play at the start of 2023.

whitePaper | March 6, 2022

Pharmaceutical companies with a medical mindset and an empowered Medical Afairs function are well equipped to meet the needs and expectations of patients and society. Yet, as capacity to understand and serve those needs accelerates.

whitePaper | October 13, 2022

Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical. The dust collector linked to the press can contribute to reliable, consistent performance

whitePaper | June 14, 2022

Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system. Characterized by demyelination and neurodegeneration that affects the communication between the brain and other parts of the body, MS leads to physical and cognitive disability.

whitePaper | November 1, 2022

Equipment cleaning in manufacturing companies is often not given the same emphasis as other processes. It can be viewed as a task.